SG11202104276YA - Peptide fragments for treatment of diabetes - Google Patents

Peptide fragments for treatment of diabetes

Info

Publication number
SG11202104276YA
SG11202104276YA SG11202104276YA SG11202104276YA SG11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA SG 11202104276Y A SG11202104276Y A SG 11202104276YA
Authority
SG
Singapore
Prior art keywords
diabetes
treatment
peptide fragments
fragments
peptide
Prior art date
Application number
SG11202104276YA
Inventor
Jan Alenfall
Maria Ekblad
Pontus Dunér
Original Assignee
Follicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum Ab filed Critical Follicum Ab
Publication of SG11202104276YA publication Critical patent/SG11202104276YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11202104276YA 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes SG11202104276YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
SG11202104276YA true SG11202104276YA (en) 2021-05-28

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104276YA SG11202104276YA (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Country Status (13)

Country Link
US (2) US20220002343A1 (en)
EP (1) EP3876970A1 (en)
JP (1) JP7553115B2 (en)
KR (1) KR20210088583A (en)
CN (1) CN113164548A (en)
AU (1) AU2019374981A1 (en)
BR (1) BR112021008888A2 (en)
CA (1) CA3116612A1 (en)
IL (1) IL282519A (en)
MX (1) MX2021005386A (en)
SG (1) SG11202104276YA (en)
WO (1) WO2020094797A1 (en)
ZA (1) ZA202102572B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
WO2023218094A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents inducing vascularisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781297A4 (en) * 1994-09-16 1999-05-19 Scripps Research Inst Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN100503637C (en) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 Glucagon-like peptide analog, its composition and its using method
US9044438B2 (en) * 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
IL270199B2 (en) * 2017-05-04 2024-07-01 Follicum Ab Peptides for treatment of diabetes

Also Published As

Publication number Publication date
WO2020094797A1 (en) 2020-05-14
EP3876970A1 (en) 2021-09-15
CN113164548A (en) 2021-07-23
US20220002343A1 (en) 2022-01-06
ZA202102572B (en) 2022-10-26
AU2019374981A1 (en) 2021-05-27
CA3116612A1 (en) 2020-05-14
JP7553115B2 (en) 2024-09-18
IL282519A (en) 2021-06-30
JP2022516400A (en) 2022-02-28
BR112021008888A2 (en) 2021-08-17
US20240327459A1 (en) 2024-10-03
MX2021005386A (en) 2021-07-06
KR20210088583A (en) 2021-07-14

Similar Documents

Publication Publication Date Title
GB201804514D0 (en) Treatment of pyroptosis
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL270199A (en) Peptides for treatment of diabetes
EP3256158A4 (en) Tolerance therapeutic for treating polypeptide induced allergy
EP3319535A4 (en) Device for fixation of bone fragments
IL282519A (en) Peptide fragments for treatment of diabetes
GB201804515D0 (en) Treatment of necroptosis
IL284029B1 (en) Peptides for treatment and prevention of diabetes and associated disorders
EP3810793A4 (en) Cyclic peptide for treating cancer
GB201805100D0 (en) Treatment of sarcopenic diseases
GB201707207D0 (en) Treatment of type 1 diabetes
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
IL263564B (en) Peptides for the treatment of osteoarthritis
IL250666B (en) Peptide for treatment of type 2 diabetes mellitus and its complications
EP3397267A4 (en) Peptides for the treatment of resorptive bone disease
IL282952A (en) Method of improving blood kinetics of peptide
EP3969027A4 (en) Polypeptides for treatment of cancer
SG11202102683XA (en) Treatment for obesity
GB201805099D0 (en) Treatment of osteoporotic diseases
GB201700849D0 (en) Citrullinated peptides for diagnosis or treatment of diabetes
GB201904282D0 (en) Treatment of osteoporotic diseases
GB201915003D0 (en) Treatment of hepatotoxicity
GB201907839D0 (en) Treatment of hepatotoxicity
GB201900811D0 (en) Treatment of hepatotoxicity
GB201805552D0 (en) Treatment of protein misfolding disease